Literature DB >> 23104224

Epigenetic progression of columnar cell lesions of the breast to invasive breast cancer.

Anoek H J Verschuur-Maes1, Peter C de Bruin, Paul J van Diest.   

Abstract

Promoter hypermethylation of several tumour suppressor genes often occurs during breast carcinogenesis, but little is known about epigenetic silencing in the possible precursor columnar cell lesion (CCL). Promoter hypermethylation of 50 different tumour suppressor genes was assessed in normal breast tissue (N = 10), CCL (N = 15), ductal carcinoma in situ (DCIS) grade I originating in CCL (N = 5) and paired CCL (N = 15) with DCIS (N = 7) and/or invasive carcinoma (N = 14) by Methylation-specific multiplex ligation-dependent probe amplification. Increasing mean cumulative methylation levels were found from normal breast tissue to CCL to DCIS and invasive carcinoma (P < 0.001) with similar methylation levels in DCIS and invasive carcinoma. Methylation levels and frequencies (in the overall analysis and analysis of only the synchronous lesions) were the highest for RASSF1, CCND2, ID4, SCGB3A1 and CDH13. The methylation levels of ID4, CCND2, and CDH13 increased significantly from normal breast tissue to CCL and to DCIS/invasive carcinoma. RASSF1, SCGB3A1 and SFRP5 had significant higher methylation levels in CCL compared to normal breast tissue, but showed no significant differences between CCL, DCIS and invasive carcinoma. Also, no difference was found between CCLs with and without atypia, or CCLs with or without synchronous cancer. In conclusion, promoter hypermethylation for several established tumour suppressor genes is already present in CCLs, underlining that promoter hypermethylation is an early event in breast carcinogenesis. Atypia in CCL or the presence of synchronous more advanced lesions does not seem to be accompanied by higher methylation levels.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23104224     DOI: 10.1007/s10549-012-2301-4

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  22 in total

1.  Aberrant promoter methylation of HIN-1 gene may contribute to the pathogenesis of breast cancer: a meta-analysis.

Authors:  Di Dai; Xi-Hua Dong; Shi-Tong Cheng; Ge Zhu; Xiao-Lin Guo
Journal:  Tumour Biol       Date:  2014-05-22

2.  DNA methylation and breast tumor clinicopathological features: The Western New York Exposures and Breast Cancer (WEB) study.

Authors:  Catherine L Callahan; Youjin Wang; Catalin Marian; Daniel Y Weng; Kevin H Eng; Meng-Hua Tao; Christine B Ambrosone; Jing Nie; Maurizio Trevisan; Dominic Smiraglia; Stephen B Edge; Peter G Shields; Jo L Freudenheim
Journal:  Epigenetics       Date:  2016-05-31       Impact factor: 4.528

3.  Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis.

Authors:  Thomas Fleischer; Arnoldo Frigessi; Kevin C Johnson; Hege Edvardsen; Nizar Touleimat; Jovana Klajic; Margit Lh Riis; Vilde D Haakensen; Fredrik Wärnberg; Bjørn Naume; Aslaug Helland; Anne-Lise Børresen-Dale; Jörg Tost; Brock C Christensen; Vessela N Kristensen
Journal:  Genome Biol       Date:  2014-08-22       Impact factor: 13.583

4.  Promoter hypermethylation using 24-gene array in early head and neck cancer: better outcome in oral than in oropharyngeal cancer.

Authors:  Rob Noorlag; Pauline M W van Kempen; Cathy B Moelans; Rick de Jong; Laura E R Blok; Ronald Koole; Wilko Grolman; Paul J van Diest; Robert J J van Es; Stefan M Willems
Journal:  Epigenetics       Date:  2014-07-08       Impact factor: 4.528

Review 5.  Inhibitor of differentiation 4 (ID4): From development to cancer.

Authors:  Divya Patel; Derrick J Morton; Jason Carey; Mathew C Havrda; Jaideep Chaudhary
Journal:  Biochim Biophys Acta       Date:  2014-12-12

Review 6.  Learning to distinguish progressive and non-progressive ductal carcinoma in situ.

Authors:  Anna K Casasent; Mathilde M Almekinders; Charlotta Mulder; Proteeti Bhattacharjee; Deborah Collyar; Alastair M Thompson; Jos Jonkers; Esther H Lips; Jacco van Rheenen; E Shelley Hwang; Serena Nik-Zainal; Nicholas E Navin; Jelle Wesseling
Journal:  Nat Rev Cancer       Date:  2022-10-19       Impact factor: 69.800

Review 7.  Progression from ductal carcinoma in situ to invasive breast cancer: revisited.

Authors:  Catherine F Cowell; Britta Weigelt; Rita A Sakr; Charlotte K Y Ng; James Hicks; Tari A King; Jorge S Reis-Filho
Journal:  Mol Oncol       Date:  2013-07-12       Impact factor: 6.603

8.  Analysis of gene copy number alterations by multiplex ligation-dependent probe amplification in columnar cell lesions of the breast.

Authors:  Anoek H J Verschuur-Maes; Cathy B Moelans; Peter C de Bruin; Paul J van Diest
Journal:  Cell Oncol (Dordr)       Date:  2014-04-02       Impact factor: 6.730

Review 9.  DNA methylation in ductal carcinoma in situ of the breast.

Authors:  Jia-Min B Pang; Alexander Dobrovic; Stephen B Fox
Journal:  Breast Cancer Res       Date:  2013-06-28       Impact factor: 6.466

10.  Development and validation of prognostic gene signature for basal-like breast cancer and high-grade serous ovarian cancer.

Authors:  Yi Zhang; Jianfang Liu; Praveen-Kumar Raj-Kumar; Lori A Sturtz; Anupama Praveen-Kumar; Howard H Yang; Maxwell P Lee; J Leigh Fantacone-Campbell; Jeffrey A Hooke; Albert J Kovatich; Craig D Shriver; Hai Hu
Journal:  Breast Cancer Res Treat       Date:  2020-09-02       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.